Type 1 Diabetes

An analysis from ADA 2023 suggests adults with T1D and higher social determinants of health risks are less likely to perform behaviors to maintain health.

David Ahn, MD, joins our hosts for a discussion on overcoming barriers with diabetes technology and offers perspective on his experience leveraging social media platforms to disseminate information as a clinician.

The AHEAD program was associated with promising reductions in mean diabetes distress scores among emerging adults with type 1 diabetes.

A combination of in-office and telehealth visits increased visit frequency and maintained glycemic control in older adults with T1D during the COVID-19 pandemic.

A recap of the top news from the 83rd Scientific Sessions of the American Diabetes Association, including data related to retatrutide, tirzepatide, oral semaglutide, and more!

Juan Frias, MD, discusses the potential impact of an FDA approval for once-weekly insulin icodec based on data observed within the ONWARDS program.

At ADA 2023, we asked interview guests for their opinions on the most important news to come from this year's scientific sessions, including Juan Frias, MD, Bob Gabbay, MD, PhD, Yehuda Handelsman, MD, Viral Shah, MD, and more.

Announced on June 28, 2023, the FDA's approval of donislecel (Lantidra) marks the first approval of an allogeneic pancreatic islet cellular therapy for the treatment of type 1 diabetes.

A 7-year longitudinal analysis presented at ADA 2023 suggests time in range was associated with an increased risk of diabetic retinopathy in people with type 1 diabetes.

Hosts are joined by Cari Berget, RN, MPH, for a deep dive into her efforts to improve the implementation of the latest diabetes technologies in real-world settings through her role as a director of the PANTHER Program.

Often overlooked and unrecognized, the mental health challenges accompanying type 1 diabetes are becoming a focal point of discussion for many in the field, including Mark Heyman, PhD, who joined Diana Isaacs, PharmD, and Natalie Bellini, DNP, for a special ADA 2023 edition of Diabetes Dialogue.

At ADA 2023, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, sat down with ADCES President-Elect Jane Dickinson, RN, PhD, to discuss her work to address shortfalls of the current language used in the management of diabetes.

At their annual meeting, the American Diabetes Association debuted updates to their Standards of Care to reflect the approval of teplizumab for delaying the onset of type 1 diabetes and underline the importance of screening for NAFLD in type 2 diabetes.

New results from the ongoing clinical trial of VX-880 suggested all patients with T1D treated with the novel stem cell-derived islet cell therapy showed restored endogenous insulin secretion and improved glycemic control.

Each month, our editorial staff compiles a recap of the top news in endocrinology from the past month. Our May 2023 month in review features new FDA approvals, important phase 2 data, and in-depth clinician perspective.

As a follow-up to an episode earlier this year and the FDA clearances of the technology that forms the iLet Bionic Pancreas, hosts sat down in the MJH Life Sciences studio for a special edition recording to explore the implications of the clearance, dispel misconceptions surrounding the system, and hypothesize about the future of this technology in people with diabetes.

Announced by the US FDA on May 19, 2023, the clearance of the iLet ACE Pump and the iLet Dosing Decision Software, when combined with a compatible CGM, will form the iLet Bionic Pancreas.

Diabetes care experts discuss practical strategies to help young adults with type 1 diabetes transition from pediatric to adult endocrinology care, and how families can support them during this transition.

Dr Julia Blanchette explains how a micro video toolkit developed by her team can help young adults alleviate the financial stress of type 1 diabetes.

Julia Blanchette, PhD, RN; Natalie Bellini, DNP, FNP-BC; and Diana Isaacs, PharmD, BC-ADM, CDCES discuss the challenges young adults with type 1 diabetes encounter, including managing their healthcare finances.

Dr Julia Blanchette highlights some of the latest advancements in automated insulin delivery systems that can aid in the self-management of type 1 diabetes.

An analysis of more than 800,000 person-years of follow-up data from people in the United Kingdom with type 1 diabetes offers an overview of cancer incidence and mortality among this cohort.

In a recent interview, Kris Kowdley, MD, discusses current data surrounding use of GLP-1 receptor agonists in NAFLD and NASH as well as the prospective role of combination agents.

In this episode, hosts sit down with Robert Vigersky, MD, chief medical officer of Medtronic Diabetes, for a discussion around the MiniMed 780G, including use, exclusive features, and how patients can obtain the new system.

A cross-sectional analysis of Medicare and commercial insurer spending suggests the in-state biosimilar production plan could be substantial in savings even after insulin cost rebates.

An analysis of NHANES data from 2009-2020 suggest approximately 75% of people with diabetes in the US were not at the American Diabetes Association-recommended HbA1c target of less than 7%.

An analysis of data from the TEDDY study suggests increased levels of moderate to vigorous physical activity could reduce risk of progression to type 1 diabetes in multiple islet autoantibody-positive children.

An analysis of data from nearly 100 adults with type 1 diabetes details associations between chronotypes and improved well-being in people with diabetes.

Pooling data from the TODAY and SEARCH studies, new research offers an overview of the challenges in access to care and outcomes among adolescents with type 1 and type 2 diabetes

An analysis of more than 1.8 million mother-offspring pairs offers new insight into a potential association between exposure to maternal depression/anxiety during pregnancy and risk of type 1 diabetes in offspring during adolescence.